XORTX’s board of directors accepted the resignation of the Former Auditor, as of January 16, 2025 and appointed the Successor Auditor as the new auditor of the Company effective January 16, 2025, and ...
Gout flares among adults in the United States are significantly underreported to healthcare providers, with nearly 72% of flares either not reported or pretreated/prevented by patients, according to ...
With the clinical development of XORLO TM1 having advanced sufficiently, including completion of a pivotal program, XORTX is initiating discussions for the XRx-026 program with the US Food and Drug ...